Dare Bioscience, Inc. (DARE) stock
DARENasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.43−0.16 (-26.57%)
Close on Nov 17, 2026Market cap $6.56MP/E –Yield –
Dare Bioscience profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Dare Bioscience's profit margin for the twelve months ending Jun 30, 2026 was -804.4%. For fiscal 2025 it was -1300.7%, against -41430.9% the year before. The highest annual figure on record is -87.8% in fiscal 2016.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -1300.7% | +40130.2 |
| FY2024 | Dec 31, 2024 | -41430.9% | −40356.7 |
| FY2023 | Dec 31, 2023 | -1074.2% | −764.7 |
| FY2022 | Dec 31, 2022 | -309.5% | −221.7 |
| FY2016 | Dec 31, 2016 | -87.8% | +29089.7 |
| FY2014 | Dec 31, 2014 | -29177.5% | +256539.2 |
| FY2013 | Dec 31, 2013 | -285716.7% | −282180.5 |
| FY2012 | Dec 31, 2012 | -3536.2% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -1590.4% | +15628.7 |
| Q1 FY2026 | Mar 31, 2026 | -1967.7% | +9311.7 |
| Q4 FY2025 | Dec 31, 2025 | -140.8% | −57680.1 |
| Q3 FY2025 | Sep 30, 2025 | -157505.1% | −84882.5 |
| Q1 FY2025 | Mar 31, 2025 | -17219.1% | −16939.4 |
| Q3 FY2024 | Sep 30, 2024 | -11279.4% | −10449.5 |
| Q2 FY2024 | Jun 30, 2024 | 57539.2% | +57535.1 |
| Q1 FY2024 | Mar 31, 2024 | -72622.6% | −72545.0 |
| Q4 FY2023 | Dec 31, 2023 | -279.8% | −259.3 |
| Q3 FY2023 | Sep 30, 2023 | -829.9% | −184.3 |
| Q2 FY2022 | Jun 30, 2022 | 4.1% | – |
| Q2 FY2017 | Jun 30, 2017 | -77.6% | – |
| Q1 FY2017 | Mar 31, 2017 | -20.5% | – |
| Q4 FY2016 | Dec 31, 2016 | -645.6% | – |
See a number that looks wrong?